SAN JOSE, Calif., March 29 /PRNewswire-FirstCall/ -- Human Pheromone Sciences, Inc. ("HPS" or "the Company") today announced results for the three months and the year ended December 31, 2009. For the three months ended December 31, 2009, net revenue was $223,000, representing a 2% decrease from revenues of $228,000 in the prior year period, and resulted in net loss of $29,000 ($0.01 per share) as compared with net loss of $58,000 ($0.01 per share) for the same period in 2008, a 50% reduction in the net loss. For the full year, net revenues of $885,000, were 11% less than revenues of $992,000 generated in the prior year. The net loss in the current year of $284,000 ($0.07 per share) was $45,000 higher than the $239,000 loss ($0.06 per share) recorded for the full year of 2008
The Company further noted that it continues to seek alternative distribution channels for its technologies and to generate marketing interest in its patent-pending sea coral based compound, classified as ER 303.
The statements in this news release may contain forward-looking statements that involve risks and uncertainties that could cause actual results to differ from predicted results. Further information on factors that could affect the Company's results is detailed in the Company's annual report to shareholders on Form 10-K for the year ended December 31, 2009 as filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements.
Human Pheromone Sciences, Inc.